Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
JAMA Psychiatry – November 04, 2020
Source: OpenAlex
Summary
A randomized controlled trial reveals psilocybin's profound potential in psychiatry. For individuals with major depressive disorder, a single psilocybin session, derived from chemical synthesis, drastically reduced symptoms. In a population of 24 adults, 71% receiving psilocybin experienced significant improvement in major depressive episodes by week four, compared to 25% in the control group. This medicine offers a new frontier in drug studies, echoing ancient contexts of psychedelic use and addressing the severe burden of depression, which has economic implications. Neurotransmitter receptor influence on behavior is key.
Abstract
ClinicalTrials.gov Identifier: NCT03181529.